Loading...

PR Information Data

Presenting a new direction for COVID-19/cancer treatment
24-03-14 10:27 913회 0건

Presenting a new direction for COVID-19/cancer treatment


2022 IVRA International Conference’ held, a great success with over 400 scholars from home and abroad attending


High-frequency hyperthermia device ‘REMISSION 1℃’ receives a global interest because of the results of COVID-19 and cancer treatment.


3731654643_1656999123.3586.png

Health and Welfare News An international conference was held in Korea where scholars from around the world gathered together to present directions for treating COVID-19 virus and cancer and share treatment results.

 

In particular, at this conference, the COVID-19 and cancer treatment results of ‘REMISSION 1℃’, a high-frequency hyperthermia device, were announced, capturing a global attention.

 

IVRA (International Virus Research Alliance) held an event on the 25th at the Trade Center (COEX) in Samseong-dong, Seoul, with about 400 people (300 domestic and 100 overseas) attending, under the theme of ‘overcoming COVID-19 and improving human health.’ It was an international medical conference.

 

IVRA (International Association for Virus Research), which consists of medical professionals from all over the world including Professor Lee Kang-hyun of Yonsei University and Wonju University, who is the chairman of IVRA and Director Yoo Seung-mo of Yesan Myeongji Hospital received a help from the company of Adipo LABs to have a successful event and invite ambassadors and commercial officials from around the world. Advisory committee members comprised of experts, including high-ranking government officials, participated and presented protocols for treatment and pain management of the COVID-19 virus and cancer. Participants shared astounding treatment results.

 

At the event, Professor Lee Kang-hyun of Yonsei University in Wonju, Professor Jang Hong-seok of the Catholic University of Korea, Dr. Yoo Seung-mo, Chairman of the Health and Healthcare Subcommittee of the Chungcheongnam-do External Cooperation Strategy Committee, Kim Seon-man, Director of Yonsei Family Love Clinic, and Dr. Nagraj of India (Chief Radiation Oncologist, Department of Radiation Oncology, Dr. Balabhai) Nanavati Hospital Mumbai, India Dr. Damodara (Chief of department of Radiation and Clinical Oncology Krishna Cancer Institute, Cuddalore and Puducherry Cancer Trust Hospital, Pondicherry), India Dr. Jebasingh Joseph Dhanaraj (MBBS, MD - Radiotherapy, DM - Oncology, Radiation Oncologist, Asirvatham Hospital, Multispeciality Hospital, Madurai), Daejeon University Seoul Oriental Hospital Professor Yoo Hwa-seung, Director Yang Jae-ho, Director Jang Hyeok-jun, Director Shin Hyeong-jin, Dr. Choi Seok-jae, Dr. Lee Hyeong-min, Dr. Malaysia Lodge (Director / Consultant Clinical Oncologist Oncology Clinic & Daycare Center), Professor Wu Zibing of China (Professor of Oncology, Zhejiang Hospital Affiliated to Zhejiang Medical University, Vice-Chairman and Secretary-General of CSCO Oncology Thermal Expert Committee), Professor Ho of Malaysia (Associate Professor & clinical oncologist/radiotherapist - University Malaya Medical Center (UMMC) and University Malaya Specialist Center), Dr. Izzati (Oncology trainee, Department of Clinical Oncology University of Malaya Medical Center (UMMC), Malaysia), and AdipoLABs CEO Han Sung-ho participated in the presentation.

 

This international conference was an academic seminar that shared the knowledge and treatment cases of domestic and foreign scholars on virus and cancer treatment. Domestic and foreign medical officials, government officials of member countries, and domestic embassy officials have come together for the event.


3731654643_1656999207.3472.png

Particularly, it was a meaningful academic seminar with the participation of many overseas VIPs, including Romania's Secretary of the Interior Arafat (Director of the National Emergency Situations Office), Jaime Cruz (Chairman of Philippine PLC Group), and Mohamed Jinna (Chairman of the UNWHD).

 

In this IVRA, the results of a study (effectiveness of hyperthermia treatment related to viral infection, cancer, and pain) conducted on 20 COVID-19 positive patients since May of last year in collaboration with the Catholic University of Korea's Seoul St. Mary's Hospital and Seosan Medical Center in South Chungcheong Province were introduced, acquiring tremendous attention.

 

 

In addition, based on the theory that hyperthermia has a positive effect on overcoming the virus when using a high-frequency hyperthermia device, an attempt was made to combine hyperthermia and immunotherapy. The high-frequency hyperthermia device 'REMISSION 1℃' was developed as a treatment to move towards the end of COVID-19. This will serve as a guide. The results have also been announced confirming that the device can treat asymptomatic or mild patients, prevent them from turning into severe cases, and prevent various diseases through immunotherapy.

 

Han Sung-ho, CEO of AdipoLABs, said, “Despite the difficulties facing the world due to the COVID-19 pandemic, REMISSION 1°C has improved the health of many COVID-19 patients. Clinical results show that no patient progressed from severe disease to death, which is a very meaningful result. It continues to show great effectiveness in cancer treatment and pain relief.”

 

Specifically, he emphasized, “We will prove its effectiveness for patients infected with the virus and cancer patients by donating REMISSION 1℃ to IVRA member countries and strive to provide overseas medical support as part of international medical sharing.”

 

A high-frequency hyperthermia device ' REMISSION 1℃' transmits high-frequency waves to the human body. Due to the intersection of + and - charges, frictional heat called 'deep core heat' is generated due to rotation, collision, and distortion of ionic charges in cells. The operating principle of REMISSION 1℃ is that when the temperature rises, blood circulation is promoted and immunity is improved. Thereby the device will treat inflammation, virus-infected cells, and cancer since cancer can be treated with heat and immunity.

 

REMISSION 1℃, a medical device that relieves pain and has fewer side effects, received official medical device approval from the Ministry of Food and Drug Safety in 2015 and is currently being used to treat numerous patients at home and abroad. The device has attracted the attention of medical officials at major domestic and international exhibitions.

 

 

링크 : http://www.whosaeng.com/137085